title: Sodium ipodate in the treatment of toxic diffuse goiter. Short-term and long-term effects on thyrotoxicosis.
abstract: Iodinated radiocontrast medication has been successful in the treatment of thyrotoxicosis when used for short periods up to 21 days, but experience with long-term use is lacking. In the first part of this study, a group of seven patients each taking 1.5 g. sodium ipodate daily was observed for 21 days and compared to a similar group of seven thyrotoxic patients taking 400 mg. propylthiouracil (PTU) daily. Sodium ipodate brought about a more significant decrease in serum total T3 and T4 levels, and more prominent increase in reverse T3 levels in the first ten days of the treatment. In the second part, a group of seven patients with thyrotoxicosis were given sodium ipodate, 1.5 g, daily for 20 days and 0.75 g. thereafter and were compared to a similar group of seven patients who took PTU, 300 mg. daily for the first 20 days and 150 mg. daily afterwards. Serum thyroid hormone levels decreased in both groups at the end of the first month of treatment, but rose again, along with worsening of symptoms, in five patients on ipodate treatment. Therefore, sodium ipodate, an iodinated radiocontrast agent is unable to control thyrotoxicosis for longer than a month.
authors.affiliation: Department of Endocrinology and Metabolic Diseases, Ankata University Medical School, Turkey.
authors.forename: N
authors.initials: N
authors.lastname: Kamel
authors.forename: A R
authors.initials: AR
authors.lastname: Uysal
authors.forename: S
authors.initials: S
authors.lastname: Koloğlu
authors.forename: G
authors.initials: G
authors.lastname: Erdoğan
authors.forename: M
authors.initials: M
authors.lastname: Senel
authors.forename: H
authors.initials: H
authors.lastname: Polat
mesh_terms: D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007487:Ipodate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011441:Propylthiouracil / Q000627:therapeutic use; D013971:Thyrotoxicosis / Q000097:blood / Q000188:drug therapy*; D013974:Thyroxine / Q000097:blood; D013997:Time Factors; D014284:Triiodothyronine / Q000097:blood
chemical_list: D014284:Triiodothyronine; D011441:Propylthiouracil; D007487:Ipodate; D013974:Thyroxine